Sigilon

Rogerio Vivaldi, M.D., President and CEO
Cambridge, MA
(NASDAQ: SGTX)
At Sigilon, we are pioneering a new class of therapeutics and seeking to develop functional cures for patients with a wide range of chronic diseases. Our Shielded Living Therapeutics™ platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies, and enzymes. Our platform technology was inspired by more than a decade of work at MIT by our academic cofounders, Bob Langer and Dan Anderson, and supported by Flagship Pioneering’s strategic vision. Together, this work paved the way for us to build a diverse pipeline spanning rare blood, lysosomal storage, and endocrine diseases. www.sigilon.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions